

BIOLASE TECHNOLOGY INC

Form 8-K

July 11, 2007

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
July 10, 2007  
Date of Report (Date of earliest event reported)  
**BIOLASE TECHNOLOGY, INC.**  
(Exact name of registrant as specified in its charter)**

**Delaware**  
(State of Incorporation)

**000-19627**  
(Commission File Number)

**87-0442441**  
(IRS Employer  
Identification Number)

**4 Cromwell**  
**Irvine, California 92618**  
(Address of principal executive offices) (Zip Code)  
**(949) 361-1200**

(Registrant's telephone number, including area code)

**Not Applicable**  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01 Other Events

SIGNATURES

---

**Table of Contents**

**Item 8.01 Other Events**

On July 10, 2007, BIOLASE Technology, Inc. ( Biolase ), issued a press release announcing that it is not aware of why there has been a significant stock price decline in recent trading sessions. President and CEO Jeffrey W. Jones said that the Company s operational results for the quarter just ended were on track and that management is looking forward to sharing its progress in detail when it announces those results. Biolase currently plans to announce its results at 6:00 AM EDT on August 7, 2007 and to hold an investor conference call at 9:00 AM EDT that same morning. Instructions to access the call will be announced next week.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOLASE TECHNOLOGY, INC.

Date: July 11, 2007

By: /s/ Jeffrey W. Jones  
Jeffrey W. Jones  
President and Chief Executive Officer

3